Facebook
Twitter
LinkedIn

Media Center

CLSI Hosts Viva Biotech Partnering Day: Zero-to-One
Facebook
Twitter
LinkedIn

May 18, 2019

Yinghong Gao, Associate Business Partner, Viva Biotech introduces speakers

The California Life Sciences Institute (CLSI) hosted its second Partnering event of 2019 with Viva Biotech on Thursday, May 18 in South San Francisco. Representatives of Viva Biotech – a Shanghai-based company that provides world-leading small molecule and biologics drug discovery CRO and biotech incubating platforms – discussed early stage investment and partnering opportunities with the company for startups and researchers.

(From left to right) Julie Harness, Litain Yeh, Dana Ault-Riche, and David Xu on the panel

The program began with a presentation by Viva Biotech Chief Business Officer, David Xu, who gave an overview of Viva Biotech’s experience with drug R&D technology platforms and their focus on investing seed to series A funding for biotech startups. Next, Litain Yeh, CEO of Laguna Hills-based Arthrosi Therapeutics, and Dana Ault-Riche, CEO of Hayward-based Reflexion Pharmaceuticals – both of whom are supported by Viva Biotech’s seed funding and/or CRO services – gave presentations on their company and the valuable partnership they share with Viva Biotech. The program wrapped up with Julie Harness, Director of Innovation Services at CLSI, joining Xu, Yeh and Ault-Riche in a panel discussing the Bay Area’s startup ecosystem and latest funding trends in the industry.

FAST company Richard Yu (left), CEO of Abalone Bio, David Xu (center), CBO of Viva Biotech, and Lin Yu, Patent Attorney of Jones Day at the networking reception

Viva Biotech Holdings, building upon its world-leading small molecule and biologics drug discovery CRO platforms, is dedicated to supporting early stage drug discovery. Viva adopts an innovative business model combining fee-for-service (FFS), equity-for-service (EFS) and direct investment approaches. Headquartered in Shanghai, with multiple incubators in China and an office in Cambridge, MA, USA., Viva can provide everything needed for a biotech startup including lab facilities, technicians, administrative support and drug R&D contract services. Since 2016, Viva has provided startup capitals in both seed and/or Series A rounds to help launch 30+ startup companies both in China and in the US. Viva is expecting to fund  30 companies in 2019.

Click here to find out more about our CRO platform, and here for our biotech investment

Submit your business plan to Yinghong Gao at Yinghong.gao@vivabiotech.com